CICC Maintains "Outperform" Rating on ALI HEALTH (00241), Raises Target Price to HK$7.1

Stock News

Nov 28, 2025

CICC has reiterated its "Outperform" rating on ALI HEALTH (00241) and raised its target price by 30% to HK$7.1, citing improved sector valuations based on a sum-of-the-parts (SOTP) valuation approach. The bank also increased its non-GAAP net profit forecasts for fiscal years 2026 and 2027 by 16% each to RMB2.48 billion and RMB2.75 billion, respectively, reflecting the company's sustained profitability efforts.

ALI HEALTH reported better-than-expected results for the first half of fiscal 2026 (ended September), with revenue reaching RMB16.697 billion, up 17% year-on-year. Non-GAAP net profit surged 38.7% to RMB1.356 billion, yielding a profit margin of 8.1%, driven by strong performance in original prescription drugs. CICC expects the company's deepening strategic partnerships with upstream enterprises to further enhance business contributions beyond product sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124460842"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124460842\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124460842?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124460842","market":"sg","top_or_hot":-1,"title":"CICC Maintains \"Outperform\" Rating on ALI HEALTH (00241), Raises Target Price to HK$7.1","media":"Stock News","content":"<p>CICC has reiterated its \"Outperform\" rating on ALI HEALTH (00241) and raised its target price by 30% to HK$7.1, citing improved sector valuations based on a sum-of-the-parts (SOTP) valuation approach. The bank also increased its non-GAAP net profit forecasts for fiscal years 2026 and 2027 by 16% each to RMB2.48 billion and RMB2.75 billion, respectively, reflecting the company's sustained profitability efforts.</p>\n<p>ALI HEALTH reported better-than-expected results for the first half of fiscal 2026 (ended September), with revenue reaching RMB16.697 billion, up 17% year-on-year. Non-GAAP net profit surged 38.7% to RMB1.356 billion, yielding a profit margin of 8.1%, driven by strong performance in original prescription drugs. CICC expects the company's deepening strategic partnerships with upstream enterprises to further enhance business contributions beyond product sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CICC Maintains \"Outperform\" Rating on ALI HEALTH (00241), Raises Target Price to HK$7.1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCICC Maintains \"Outperform\" Rating on ALI HEALTH (00241), Raises Target Price to HK$7.1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-28 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CICC has reiterated its \"Outperform\" rating on ALI HEALTH (00241) and raised its target price by 30% to HK$7.1, citing improved sector valuations based on a sum-of-the-parts (SOTP) valuation approach. The bank also increased its non-GAAP net profit forecasts for fiscal years 2026 and 2027 by 16% each to RMB2.48 billion and RMB2.75 billion, respectively, reflecting the company's sustained profitability efforts.</p>\n<p>ALI HEALTH reported better-than-expected results for the first half of fiscal 2026 (ended September), with revenue reaching RMB16.697 billion, up 17% year-on-year. Non-GAAP net profit surged 38.7% to RMB1.356 billion, yielding a profit margin of 8.1%, driven by strong performance in original prescription drugs. CICC expects the company's deepening strategic partnerships with upstream enterprises to further enhance business contributions beyond product sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1610","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1124460842","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124460842","pubTimestamp":1764315866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CICC has reiterated its \"Outperform\" rating on ALI HEALTH (00241) and raised its target price by 30% to HK$7.1, citing improved sector valuations based on a sum-of-the-parts (SOTP) valuation...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1610":"ETF&股票定投概念","00241":"阿里健康","BK1142":"互联网与直销零售","BK1502":"双十一","BK1591":"就地过年概念","BK1247":"药品零售","BK1615":"港股-互联网","BK1189":"医疗保健技术","BK1584":"蚂蚁金服概念","BK1589":"北水核心资产","BK1571":"互联网医疗","BK1501":"阿里概念股","BK1617":"AI医疗","BK1515":"抗疫概念"},"translate_title":"中金维持阿里健康(00241)“跑赢大市”评级，目标价升至7.1港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"CICC has reiterated its \"Outperform\" rating on ALI HEALTH (00241) and raised its target price by 30% to HK$7.1, citing improved sector valuations based on a sum-of-the-parts (SOTP) valuation approach. The bank also increased its non-GAAP net profit forecasts for fiscal years 2026 and 2027 by 16% each to RMB2.48 billion and RMB2.75 billion, respectively, reflecting the company's sustained profitability efforts.\nALI HEALTH reported better-than-expected results for the first half of fiscal 2026 (ended September), with revenue reaching RMB16.697 billion, up 17% year-on-year. Non-GAAP net profit surged 38.7% to RMB1.356 billion, yielding a profit margin of 8.1%, driven by strong performance in original prescription drugs. CICC expects the company's deepening strategic partnerships with upstream enterprises to further enhance business contributions beyond product sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}